Russian Meningitis Vaccine Shortages

20 January 1997

Over 4,000 Russians, mainly children, have been infected with meningitiscaused by the serogroup A meningococcus in the last 10 months, with 26 deaths recorded so far. The infection started in the city and has now spread to several republics, including those bordering China.

Immunization programs face continued severe vaccine shortages; only 150,000 doses are available from Moscow, sourced from the Gabricheviskiy Institute, for the rest of the country, with the actual requirement put nearer 600,000 doses. The price per 1,000 doses of vaccine is put at 2.5 million roubles ($44,550), but press reports say the health department seems to be slow in providing financing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight